Comparison of enterovirus-specific cellular immunity in two populations of young children vaccinated with inactivated or live poliovirus vaccines.
Enterovirus-specific cellular immunity was studied in Estonian and in Finnish children at the age of 9 months. The aim was to evaluate the level of responsiveness in two neighbouring countries with different poliovirus immunization practices and striking differences in the incidence of insulin-dependent diabetes mellitus (IDDM), a disease in which early enterovirus infections are an aetiological risk factor. The Estonian children immunized with live attenuated polio vaccine had stronger T cell responses to coxsackievirus B4 and poliovirus type 1 when compared with Finnish children immunized with inactivated polio vaccine (median stimulation indices 10.4 and 6.3 in Estonian children and 1.9 and 2.9 in Finnish children, respectively; P < 0.05). Lymphocytes stimulated by poliovirus type 1 antigen expressed interferon-gamma (IFN-gamma) mRNAs, which strongly correlated with the level of proliferation responses. Lymphocytes of Estonian children had a tendency towards stronger expression of IFN-gamma upon poliovirus challenge when compared with Finnish children. The number of children who had experienced coxsackievirus B infections, as determined by the presence of neutralizing antibodies, did not differ between Estonian and Finnish children. The results show that Finnish children have weaker cellular immunity against enteroviruses at the age of 9 months compared with Estonian children at the same age. This is most probably due to the difference in polio vaccination schedules; in Estonia live poliovirus vaccine is used and given at earlier ages than the inactivated vaccines in Finland. This leads to stronger T cell immunity which cross-reacts with other enterovirus serotypes. This may explain the lower incidence of IDDM in Estonia by providing effective protection against diabetogenic enterovirus strains in Estonian children.
Turku Immunology Centre, Department of Virology, University of Turku, Finland. sirpa.juhela@utu.fi
S
S
Juhela
H
H
Hyöty
R
R
Uibo
S H
SH
Meriste
O
O
Uibo
M
M
Lönnrot
M
M
Halminen
O
O
Simell
J
J
Ilonen
D000914:Antibodies, Viral / Q000097:blood; D001327:Autoimmune Diseases / Q000453:epidemiology; D003922:Diabetes Mellitus, Type 1 / Q000453:epidemiology; D029822:Enterovirus B, Human / Q000276:immunology*; D004957:Estonia / Q000453:epidemiology; D005387:Finland / Q000453:epidemiology; D006801:Humans; D007111:Immunity, Cellular; D015994:Incidence; D007223:Infant; D007371:Interferon-gamma / Q000096:biosynthesis / Q000235:genetics; D015847:Interleukin-4 / Q000096:biosynthesis; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000378:metabolism; D011043:Pokeweed Mitogens / Q000276:immunology; D017955:Poliovirus / Q000276:immunology*; D011054:Poliovirus Vaccine, Inactivated / Q000276:immunology*; D011055:Poliovirus Vaccine, Oral / Q000276:immunology*; D012333:RNA, Messenger / Q000096:biosynthesis; D013745:Tetanus Toxoid / Q000276:immunology; D014611:Vaccination
D000914:Antibodies, Viral; D008222:Lymphokines; D011043:Pokeweed Mitogens; D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral; D012333:RNA, Messenger; D013745:Tetanus Toxoid; D015847:Interleukin-4; D007371:Interferon-gamma